Wells Fargo & Company Surrozen, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.44 - $0.89 $0 - $1	2 Added 1.52%	134 $0
Q2 2023 Aug 15, 2023	SELL	$0.55 - $0.72 $8 - $11	-16 Reduced 10.81%	132 $0
Q1 2023 May 12, 2023	BUY	$0.56 - $1.32 $1 - $2	2 Added 1.37%	148 $0
Q4 2022 Feb 13, 2023	BUY	$0.42 - $41.25 $1 - $165	4 Added 2.82%	146 $0
Q3 2022 Nov 14, 2022	SELL	$0.26 - $46.35 $1 - $185	-4 Reduced 2.74%	142 $0
Q2 2022 Aug 12, 2022	BUY	$2.14 - $3.43 $25 - $41	12 Added 8.96%	146 $0
Q1 2022 May 16, 2022	SELL	$2.2 - $6.01 $11 - $30	-5 Reduced 3.6%	134 $0
Q4 2021 Feb 14, 2022	BUY	$6.0 - $9.92 $36 - $59	6 Added 4.51%	139 $1,000
Q3 2021 Nov 15, 2021	BUY	$6.98 - $12.03 $928 - $1,599	133 New	133 $1,000

4.52M

Ticker SRZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,122,900
Market Cap $371M
Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, a...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.